Incyte (INCY) to Release Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY) will likely be posting its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of $1.40 per share and revenue of $1.2346 billion for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The firm had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The company’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.43 EPS. On average, analysts expect Incyte to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Incyte Price Performance

Shares of INCY opened at $96.92 on Tuesday. Incyte has a 52 week low of $56.13 and a 52 week high of $112.29. The company has a current ratio of 3.32, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The firm has a market cap of $19.29 billion, a price-to-earnings ratio of 15.12, a PEG ratio of 0.78 and a beta of 0.85. The stock has a 50 day moving average of $96.45 and a 200-day moving average of $98.32.

Insider Activity at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $94.24, for a total value of $1,759,178.08. Following the completion of the sale, the insider owned 234,800 shares in the company, valued at $22,127,552. This represents a 7.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 17.80% of the company’s stock.

Institutional Trading of Incyte

A number of institutional investors and hedge funds have recently made changes to their positions in INCY. T. Rowe Price Investment Management Inc. acquired a new position in shares of Incyte during the 4th quarter valued at about $65,000. Compound Planning Inc. increased its holdings in Incyte by 36.8% in the 4th quarter. Compound Planning Inc. now owns 3,653 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 983 shares during the period. Invesco Ltd. increased its holdings in Incyte by 13.2% in the 4th quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company’s stock valued at $343,105,000 after buying an additional 405,611 shares during the period. Birchwood Financial Partners Inc. acquired a new position in shares of Incyte in the 4th quarter valued at $115,000. Finally, Corient Private Wealth LLC lifted its holdings in shares of Incyte by 18.6% during the 4th quarter. Corient Private Wealth LLC now owns 37,827 shares of the biopharmaceutical company’s stock worth $3,736,000 after acquiring an additional 5,938 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

INCY has been the topic of several research analyst reports. Wall Street Zen cut Incyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Royal Bank Of Canada lowered their target price on shares of Incyte from $95.00 to $92.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 11th. Stifel Nicolaus increased their target price on shares of Incyte from $119.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Incyte in a research report on Wednesday, April 15th. Finally, Wells Fargo & Company lowered their price objective on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 11th. Ten analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $104.89.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.